Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy

Natural Killer (NK) cells are a type of innate lymphoid cells that play a crucial role in immunity by killing virally infected or tumor cells and secreting cytokines and chemokines. NK cell-mediated immunotherapy has emerged as a promising approach for cancer treatment due to its safety and effectiv...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1207276
Main Authors Zhang, Minchuan, Lam, Kong-Peng, Xu, Shengli
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 09.08.2023
Subjects
cancer
functionality
Immunology
immunotherapy
manufacturability
natural killer (NK) cell
NK cell engager (NKCE)
Online AccessGet full text

Cover

Abstract Natural Killer (NK) cells are a type of innate lymphoid cells that play a crucial role in immunity by killing virally infected or tumor cells and secreting cytokines and chemokines. NK cell-mediated immunotherapy has emerged as a promising approach for cancer treatment due to its safety and effectiveness. NK cell engagers (NKCEs), such as BiKE (bispecific killer cell engager) or TriKE (trispecific killer cell engager), are a novel class of antibody-based therapeutics that exhibit several advantages over other cancer immunotherapies harnessing NK cells. By bridging NK and tumor cells, NKCEs activate NK cells and lead to tumor cell lysis. A growing number of NKCEs are currently undergoing development, with some already in clinical trials. However, there is a need for more comprehensive studies to determine how the molecular design of NKCEs affects their functionality and manufacturability, which are crucial for their development as off-the-shelf drugs for cancer treatment. In this review, we summarize current knowledge on NKCE development and discuss critical factors required for the production of effective NKCEs.
AbstractList Natural Killer (NK) cells are a type of innate lymphoid cells that play a crucial role in immunity by killing virally infected or tumor cells and secreting cytokines and chemokines. NK cell-mediated immunotherapy has emerged as a promising approach for cancer treatment due to its safety and effectiveness. NK cell engagers (NKCEs), such as BiKE (bispecific killer cell engager) or TriKE (trispecific killer cell engager), are a novel class of antibody-based therapeutics that exhibit several advantages over other cancer immunotherapies harnessing NK cells. By bridging NK and tumor cells, NKCEs activate NK cells and lead to tumor cell lysis. A growing number of NKCEs are currently undergoing development, with some already in clinical trials. However, there is a need for more comprehensive studies to determine how the molecular design of NKCEs affects their functionality and manufacturability, which are crucial for their development as off-the-shelf drugs for cancer treatment. In this review, we summarize current knowledge on NKCE development and discuss critical factors required for the production of effective NKCEs.
Author Zhang, Minchuan
Xu, Shengli
Lam, Kong-Peng
AuthorAffiliation 3 School of Biological Sciences, College of Science, Nanyang Technological University , Singapore , Singapore
1 Singapore Immunology Network, Agency for Science, Technology, and Research , Singapore , Singapore
2 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore , Singapore , Singapore
4 Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore , Singapore , Singapore
AuthorAffiliation_xml – name: 3 School of Biological Sciences, College of Science, Nanyang Technological University , Singapore , Singapore
– name: 4 Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore , Singapore , Singapore
– name: 1 Singapore Immunology Network, Agency for Science, Technology, and Research , Singapore , Singapore
– name: 2 Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore , Singapore , Singapore
Author_xml – sequence: 1
  givenname: Minchuan
  surname: Zhang
  fullname: Zhang, Minchuan
– sequence: 2
  givenname: Kong-Peng
  surname: Lam
  fullname: Lam, Kong-Peng
– sequence: 3
  givenname: Shengli
  surname: Xu
  fullname: Xu, Shengli
BookMark eNpVkcFPHCEUxkljk6r1H-hpjnrYFXjAgBdjNttq3NhLeyYsMCtmBlaY0fjfy7qbpnLhhffl9_Hed4KOYooeoR8EzwGkuuzCMExziinMCcUtbcUXdEyEYDOglB39V39DZ6U84XqYAgB-jFYPZpyy6Zv70Pc-Nwvf980ybszG59KcP9wvluXiqjFN9K9Nl1McQ1WF2FgT7a6q1jGNjz6b7dt39LUzffFnh_sU_f25_LO4na1-_7pb3KxmljExziQ2AiSXhDi-llI4JTn2QEBwLi3QDpgjWOLWGyGtddhx0TFDleKUci7gFN3tuS6ZJ73NYTD5TScT9MdDyhtt8hhs7zW1qqOsdcTRjrVGqXVb8VCdrRJrRyvres_aTuvBO-vjWNfxCfq5E8Oj3qQXTTDjGMPuN-cHQk7Pky-jHkKxdY8m-jQVTeuoDLfQQpXSvdTmVEr23T8fgvUuS_2Rpd5lqQ9Zwjsaq5Ma
CitedBy_id crossref_primary_10_1136_jitc_2023_008295
crossref_primary_10_1002_bab_2623
crossref_primary_10_20517_jtgg_2023_25
crossref_primary_10_3389_fimmu_2024_1384039
crossref_primary_10_3389_fimmu_2024_1358668
crossref_primary_10_1111_jcmm_18470
crossref_primary_10_1038_s41571_024_00905_y
Cites_doi 10.1080/19420862.2020.1752529
10.1016/j.ebiom.2020.102975
10.1097/01.HS9.0000846252.68296.03
10.1089/cbr.2012.1329
10.1158/1538-7445.AM2017-5671
10.1126/science.1068440
10.1080/19420862.2021.1967714
10.1136/jitc-2020-001930
10.4103/jcrt.jcrt_52_21
10.3389/fonc.2022.906251
10.1073/pnas.0502439102
10.1182/blood.V90.3.1109
10.1002/hep.30347
10.1126/scitranslmed.aat5775
10.4110/in.2022.22.e4
10.1155/2016/7470124
10.3389/fimmu.2016.00413
10.1038/leu.2013.188
10.1038/ni1402
10.1073/pnas.85.16.5879
10.3390/cancers13163994
10.4049/jimmunol.173.9.5349
10.3389/fonc.2018.00086
10.1182/blood-2012-01-400515
10.4049/jimmunol.156.8.2948
10.3389/fimmu.2021.707542
10.1080/2162402X.2014.1001224
10.1016/j.cell.2018.10.014
10.1126/science.aaz9356
10.1200/JCO.2014.57.3329
10.1016/j.molimm.2015.01.003
10.1038/nbt.2621
10.1158/2159-8290.CD-15-0944
10.1200/JCO.2003.05.013
10.3390/cancers12103041
10.1146/annurev-immunol-020711-075005
10.1186/s40364-022-00364-6
10.3389/fimmu.2018.00814
10.1097/CJI.0000000000000320
10.1182/blood-2021-148869
10.3389/fimmu.2018.00441
10.1158/0008-5472.CAN-10-4179
10.1186/s13045-022-01382-5
10.1074/jbc.M308491200
10.1126/sciadv.aba8564
10.1182/blood-2005-08-027979
10.1016/j.jhep.2009.12.005
10.1111/bph.15222
10.1084/jem.20131601
10.1038/nrc.2015.5
10.3389/fimmu.2022.1083462
10.1182/blood-2018-99-118970
10.1158/1538-7445.AM2022-CT003
10.1074/jbc.M700820200
10.1016/j.jbiotec.2006.09.013
10.1016/j.copbio.2011.06.012
10.1182/blood-2004-10-4100
10.1158/2326-6066.CIR-17-0649
10.3389/fimmu.2018.01009
10.1038/s41375-020-0734-z
10.4049/jimmunol.146.5.1571
10.3389/fimmu.2015.00507
10.3390/antib8030043
10.1016/j.ymeth.2005.01.001
10.1038/s41568-022-00491-0
10.3390/antib7020018
10.1093/protein/gzx043
10.1084/jem.190.10.1505
10.1172/JCI114727
10.1083/jcb.201712085
10.1158/0008-5472.CAN-05-3521
10.1182/blood.V128.22.1836.1836
10.1056/NEJMe0806778
10.1172/JCI119616
10.1016/j.molimm.2006.05.009
10.1182/blood-2005-05-2177
10.1016/j.ymthe.2021.06.018
10.1182/blood.V120.21.256.256
10.1158/1538-7445.AM2019-4972
10.1080/19420862.2018.1466767
10.4049/jimmunol.2101139
10.3389/fimmu.2021.669496
10.1016/j.mam.2020.100870
10.1038/s41573-019-0028-1
10.1016/j.drudis.2018.02.012
10.1158/2326-6066.CIR-21-0843
10.1182/asheducation-2016.1.106
10.1038/nbt1127
10.1158/1538-7445.AM2016-580
10.1111/imr.12520
10.1038/nri2155
10.1200/JCO.2007.14.8957
10.3390/cancers12092659
10.3390/antib7030028
10.1021/ac7018624
10.7554/eLife.52337.sa2
10.1038/s41392-017-0002-5
10.1007/978-1-4939-3684-7_28
10.4049/jimmunol.170.6.2862
10.1182/blood-2019-128749
10.1002/ijc.21382
10.3389/fimmu.2022.1039969
10.20892/j.issn.2095-3941.2020.0399
10.1074/jbc.M115.678912
10.4161/mabs.28591
10.1126/scitranslmed.aaf2341
10.2147/DDDT.S151282
10.1093/protein/9.7.617
10.1016/j.immuni.2017.10.008
10.3390/cancers13215446
10.1038/ncomms6479
10.18632/oncotarget.12073
10.1158/1078-0432.CCR-17-3117
10.1038/s41375-021-01478-w
10.3390/cells12070996
10.1016/S1470-2045(19)30320-1
10.1038/s41571-019-0182-8
10.1016/S1074-7613(02)00333-3
10.1016/0076-6879(91)03005-2
10.1186/s12943-020-1144-6
10.1002/0471142735.im1109bs90
10.4049/jimmunol.2001004
10.1084/jem.188.3.549
10.1182/blood-2022-164753
10.4049/jimmunol.1300313
10.1158/0008-5472.CAN-16-0839
10.3791/52502-v
10.1080/19420862.2021.1950264
10.1021/acsami.1c08986
10.4143/crt.2016.491
10.3390/cells10071667
10.4049/jimmunol.0904117
10.1158/1535-7163.MCT-07-2384
10.3389/fbioe.2021.796991
10.3389/fimmu.2019.00909
10.4049/jimmunol.1502438
10.1158/1078-0432.CCR-13-0505
10.1182/blood-2014-12-614636
10.4049/jimmunol.151.11.6429
10.1074/jbc.271.26.15682
10.1158/1078-0432.CCR-21-0164
10.1038/s41598-022-09324-4
10.3892/ol.2019.10903
10.1093/protein/gzp094
10.1073/pnas.012681099
10.1182/bloodadvances.2018029371
10.1038/nri2381
10.1074/jbc.M110.117382
10.3389/fimmu.2012.00377
10.3389/fonc.2022.739976
10.3389/fimmu.2012.00051
10.21037/atm.2019.01.42
10.4049/jimmunol.168.2.671
10.1038/s41590-018-0132-0
10.1158/1078-0432.CCR-14-1860
10.1158/1535-7163.MCT-12-0692
10.1186/s13045-018-0677-2
10.1182/blood.V128.22.4513.4513
10.1080/2162402X.2018.1424677
10.3390/cells9030753
10.1186/s12943-022-01663-0
10.1189/jlb.0903428
10.1111/imr.12015
10.1093/protein/6.8.989
10.1080/13696998.2019.1582059
10.1158/1078-0432.CCR-15-2710
10.1182/blood.V99.3.754
10.1038/sj.leu.2404499
10.1182/blood-2004-09-3548
10.1016/j.bbapap.2014.07.005
10.1016/S1074-7613(00)70060-4
10.1128/MCB.24.12.5144-5156.2004
10.2165/00063030-200822050-00004
10.1038/s41375-020-01065-5
10.1080/10428194.2022.2095623
10.7150/ijbs.34213
10.1111/iji.12461
10.3390/antib11010012
10.1038/emm.2017.35
10.3389/fimmu.2016.00351
10.1182/blood-2012-04-425397
10.1084/jem.20150792
10.1038/nri2868
10.1016/j.imlet.2011.02.003
10.1016/j.cell.2019.04.041
10.1182/blood-2005-04-1351
10.1002/bip.22879
10.18632/oncotarget.5135
10.1038/ncomms12878
10.1111/trf.14569
10.1016/S1074-7613(00)80574-9
10.1016/S1074-7613(00)00038-8
10.1080/2162402X.2020.1854529
10.1172/JCI45816
10.1182/blood-2022-170193
10.2165/00063030-200923020-00003
10.1016/j.it.2022.09.007
10.1186/s40364-021-00332-6
10.1016/j.intimp.2011.08.016
10.1007/s11523-015-0391-8
10.1073/pnas.90.14.6444
10.1038/s41423-020-0417-8
10.3390/ijms21238914
10.1182/bloodadvances.2018018176
10.1084/jem.178.3.1121
10.1158/1557-3125.HIPPO19-IA12
10.1208/s12248-022-00744-8
10.1016/j.xphs.2018.12.014
10.3389/fonc.2021.720501
10.1038/s41598-020-66806-z
10.1016/j.immuni.2020.08.001
10.4049/jimmunol.171.12.6891
10.1093/protein/gzq118
10.1002/JLB.MR0718-269R
10.1038/ni.2621
10.1038/s41577-018-0061-z
10.1186/s13045-015-0188-3
10.3390/cancers14174318
10.1084/jem.20181454
10.1182/blood-2013-10-533398
10.1038/mto.2016.15
10.1007/s10930-013-9502-5
10.1084/jem.192.3.337
10.1038/ni929
10.1038/s41423-019-0206-4
10.1186/s12967-019-1917-0
ContentType Journal Article
Copyright Copyright © 2023 Zhang, Lam and Xu 2023 Zhang, Lam and Xu
Copyright_xml – notice: Copyright © 2023 Zhang, Lam and Xu 2023 Zhang, Lam and Xu
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fimmu.2023.1207276
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
EndPage 1207276
ExternalDocumentID oai_doaj_org_article_2c9f247d1d2f47a99b7f3431d5c96bd2
10_3389_fimmu_2023_1207276
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c446t-80a6385811d5b886d9850e3136558c32f34d10807ea68ccd0d56f4a2995225563
IEDL.DBID RPM
ISSN 1664-3224
IngestDate Tue Oct 22 15:15:35 EDT 2024
Tue Sep 17 21:29:37 EDT 2024
Thu Oct 24 23:31:59 EDT 2024
Fri Nov 22 00:14:49 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c446t-80a6385811d5b886d9850e3136558c32f34d10807ea68ccd0d56f4a2995225563
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: David Wald, Case Western Reserve University, United States
Reviewed by: Bruce Walcheck, University of Minnesota Twin Cities, United States; Stephen Gillies, Provenance Biopharmaceuticals, United States; Ignazio Caruana, University Children’s Hospital Würzburg, Germany
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450036/
PQID 2858407373
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_2c9f247d1d2f47a99b7f3431d5c96bd2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10450036
proquest_miscellaneous_2858407373
crossref_primary_10_3389_fimmu_2023_1207276
PublicationCentury 2000
PublicationDate 2023-08-09
PublicationDateYYYYMMDD 2023-08-09
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-09
  day: 09
PublicationDecade 2020
PublicationTitle Frontiers in immunology
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Galandrini (B45) 2005; 106
Dingman (B224) 2019; 108
Le Bouteiller (B135) 2002; 99
Sedykh (B221) 2018; 12
Susa (B182) 2020; 9
Beatty (B175) 2015; 21
Cai (B72) 2022; 24
Gauthier (B79) 2019; 177
Wu (B68) 2015; 8
Wang (B67) 2020; 43
Felices (B63) 2019; 3
Shah (B176) 2020; 34
Cartron (B28) 2002; 99
Wang (B5) 2016; 3
Lin (B85) 2022; 6
Huizinga (B101) 1990; 86
Barakonyi (B136) 2004; 173
Arvindam (B61) 2021; 35
Shibuya (B139) 1996; 4
Arslan (B188) 2022; 12
Dennehy (B123) 2011; 186
Gleason (B50) 2014; 123
Wu (B12) 1997; 100
Blunt (B131) 2020; 47
Liu (B166) 2020; 10
Long (B130) 2013; 31
Khawar (B34) 2021; 12
Tijink (B212) 2008; 7
Lanier (B44) 1991; 146
Lo Nigro (B26) 2019; 7
Foster (B114) 2003; 278
Li (B193) 2020; 17
Lu (B1) 2022; 21
McCann (B177) 2003; 170
Kronqvist (B207) 2010; 24
Zhang (B100) 2000; 13
Vogel (B35) 2014; 28
Wensveen (B37) 2018; 9
Creelan (B155) 2019; 16
Doubrovina (B151) 2003; 171
Hagihara (B191) 2014; 1844
Peruzzi (B97) 2013; 191
Messersmith (B27) 2008; 359
Vallera (B57) 2020; 12
Béziat (B127) 2015; 6
Zhang (B157) 2018; 19
Pang (B16) 2022; 14
Kakiuchi-Kiyota (B73) 2022; 36
Bacac (B173) 2016; 128
Weng (B30) 2003; 21
Ghasemi (B89) 2016; 7
Gantke (B77) 2017; 30
Zhang (B32) 2022; 10
Muntasell (B128) 2016; 196
Nikkhoi (B36) 2022; 13
Wang (B120) 2018; 24
Pinto (B15) 2022; 43
Grönwall (B206) 2007; 128
Deng (B122) 2015; 290
Klinger (B210) 2012; 119
Ruggeri (B22) 2002; 295
Hwang (B223) 2005; 36
Chen (B144) 2004; 24
Tang (B190) 1996; 271
Chiossone (B18) 2018; 18
Binz (B205) 2005; 23
Chan (B54) 2018; 6
Zheng (B170) 2015; 96
Hay (B7) 2019; 22
Garrity (B104) 2005; 102
Das (B159) 2017; 276
Laskowski (B39) 2022; 22
Felices (B189) 2016; 1441
Maïza (B138) 1993; 178
Conlon (B147) 2015; 33
Frejd (B204) 2017; 49
Orange (B169) 2008; 8
Romee (B150) 2016; 8
Giang (B58) 2022; 140
Romee (B96) 2013; 121
Gleason (B52) 2012; 11
Miller (B171) 2020; 12
Sivori (B132) 2021; 80
Kontermann (B209) 2011; 22
Westgaard (B113) 2004; 76
Vallera (B56) 2021; 13
Jia (B201) 2012; 12
Holliger (B187) 1993; 90
Prager (B21) 2019; 216
Asaadi (B203) 2021; 9
Vance (B11) 1993; 151
Schmidt (B149) 2012; 3
Song (B87) 2021; 13
Au (B88) 2020; 6
Huston (B184) 1991; 203
Welte (B121) 2006; 7
Pende (B141) 2005; 105
Watkins-Yoon (B83) 2019; 134
Gopal (B225) 2013; 32
Zheng (B160) 2019; 17
Jiang (B161) 2022; 12
Sutherland (B105) 2002; 168
Sarhan (B158) 2016; 76
Astaneh (B168) 2022; 18
Davis (B195) 2010; 23
Ceppi (B8) 2018; 58
Easom (B146) 2018; 9
von Strandmann (B90) 2006; 107
Labrijn (B219) 2019; 18
Orlova (B208) 2006; 66
Deguine (B107) 2013; 251
Moon (B222) 2022; 22
Ellwanger (B93) 2016; 76
Grzywacz (B95) 2007; 21
Spiess (B218) 2015; 67
Zhang (B140) 2015; 212
Zheng (B153) 2019; 18
Gantke (B76) 2016; 128
Parolini (B143) 2000; 192
Zhao (B9) 2018; 11
Raynaud (B78) 2020; 10
Platonova (B116) 2011; 71
Watzl (B102) 2010; 90
Abaandou (B227) 2021; 10
Lin (B119) 2022; 140
Gantke (B71) 2017; 77
Raitman (B43) 2021; 138
Waggoner (B142) 2012; 3
Pereira (B31) 2018; 10
Phillips (B112) 2016; 106
Zamai (B115) 2020; 9
Sasse (B92) 2022; 63
Wang (B220) 2019; 8
Ren (B3) 2020; 19
Toffoli (B55) 2021; 13
Kato (B172) 2020; 53
Reusch (B42) 2022; 11
Jay (B180) 2018; 7
Prager (B20) 2019; 105
Roopenian (B216) 2007; 7
Le Bouteiller (B137) 2011; 138
Krah (B198) 2018; 7
Mamessier (B118) 2011; 121
Lanier (B125) 1998; 8
Heath (B129) 2016; 2016
Reth (B179) 2013; 14
Tu (B134) 2015; 212
Jiang (B154) 2022; 12
Srpan (B98) 2018; 217
Cartwright (B178) 2014; 5
Wiernik (B99) 2013; 19
Schmohl (B60) 2016; 7
Quintero-Hernández (B202) 2007; 44
Shen (B183) 2008; 80
Bachmann (B200) 2010; 10
Spiess (B199) 2013; 31
Roman Aguilera (B164) 2018; 7
Rothe (B91) 2015; 125
Ridgway (B194) 1996; 9
Surowka (B197) 2021; 13
Nieto (B215) 2022; 82
Musolino (B29) 2008; 26
Draghi (B84) 2019; 79
Rougé (B181) 2020; 367
Sun (B165) 2019; 70
Whitlow (B186) 1993; 6
Li (B25) 2022; 13
Huston (B185) 1988; 85
Ju (B162) 2010; 52
Arulanandam (B86) 2023; 12
Cheng (B64) 2020; 17
Pende (B109) 1999; 190
van der Horst (B217) 2020; 12
Ma (B6) 2019; 15
Chiu (B62) 2021; 29
Ye (B148) 2018; 3
Wu (B17) 2020; 19
Tan (B226) 2021; 9
de Haas (B14) 1996; 156
Zheng (B4) 2018; 23
Morvan (B10) 2016; 16
Mehta (B23) 2016; 2016
Bogen (B81) 2021; 12
Wiernik (B51) 2012; 120
Koene (B13) 1997; 90
Xie (B41) 2020; 59
Ross (B94) 2018; 132
Suresh (B192) 1986
Wingert (B70) 2021; 13
Pinheiro (B111) 2020; 177
Lamers-Kok (B24) 2022; 15
Seidel (B2) 2018; 8
Arnone (B48) 2021; 9
Blunt (B133) 2022; 209
Oberg (B74) 2018; 9
Barrow (B110) 2019; 10
Pekar (B82) 2021; 206
Billadeau (B103) 2003; 4
Sivori (B124) 2019; 16
Holdenrieder (B108) 2006; 118
Rocca (B145) 2016; 7
Blake (B167) 2016; 6
Bryceson (B47) 2006; 107
Della Chiesa (B126) 2016; 7
Veronese (B214) 2008; 22
Kerbauy (B40) 2021; 27
Kuwahara (B75) 2020; 21
Don Yun (B65) 2018; 2
Müller (B211) 2007; 282
Freud (B19) 2017; 47
Colomar-Carando (B80) 2022; 10
Reusch (B69) 2014; 6
Jamieson (B106) 2002; 17
Vallera (B38) 2016; 22
Pesce (B152) 2015; 4
Vallera (B49) 2013; 28
Schmohl (B59) 2017; 49
Bagot (B163) 2019; 20
Schmohl (B53) 2016; 11
André (B156) 2018; 175
Gunasekaran (B196) 2010; 285
Slaga (B174) 2018; 10
Billadeau (B46) 1998; 188
Kontermann (B213) 2009; 23
Lu (B33) 2021; 11
Fauriat (B117) 2006; 109
Peipp (B66) 2015; 6
References_xml – volume: 12
  start-page: 1752529
  year: 2020
  ident: B171
  article-title: Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats
  publication-title: MAbs
  doi: 10.1080/19420862.2020.1752529
  contributor:
    fullname: Miller
– volume: 59
  year: 2020
  ident: B41
  article-title: CAR-NK cells: a promising cellular immunotherapy for cancer
  publication-title: eBioMedicine
  doi: 10.1016/j.ebiom.2020.102975
  contributor:
    fullname: Xie
– volume: 6
  year: 2022
  ident: B85
  article-title: P842: novel multifunctional tetravalent Cd38 Nkp46 flex-nk engagers actively target and kill multiple myeloma cells
  publication-title: Hemasphere
  doi: 10.1097/01.HS9.0000846252.68296.03
  contributor:
    fullname: Lin
– volume: 28
  year: 2013
  ident: B49
  article-title: Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells
  publication-title: Cancer Biother Radiopharm
  doi: 10.1089/cbr.2012.1329
  contributor:
    fullname: Vallera
– volume: 77
  year: 2017
  ident: B71
  article-title: Abstract 5671: AFM26 - a novel CD16A-directed bispecific TandAb targeting BCMA for multiple myeloma
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2017-5671
  contributor:
    fullname: Gantke
– volume: 295
  year: 2002
  ident: B22
  article-title: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
  publication-title: Science
  doi: 10.1126/science.1068440
  contributor:
    fullname: Ruggeri
– volume: 13
  start-page: 1967714
  year: 2021
  ident: B197
  article-title: Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins
  publication-title: MAbs
  doi: 10.1080/19420862.2021.1967714
  contributor:
    fullname: Surowka
– volume: 9
  year: 2021
  ident: B48
  article-title: Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001930
  contributor:
    fullname: Arnone
– volume: 18
  year: 2022
  ident: B168
  article-title: Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: an: in vitro: study
  publication-title: J Cancer Res Ther
  doi: 10.4103/jcrt.jcrt_52_21
  contributor:
    fullname: Astaneh
– volume: 12
  year: 2022
  ident: B154
  article-title: Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.906251
  contributor:
    fullname: Jiang
– volume: 102
  year: 2005
  ident: B104
  article-title: The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.0502439102
  contributor:
    fullname: Garrity
– volume: 90
  year: 1997
  ident: B13
  article-title: Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell fc gammaRIIIa, independently of the fc gammaRIIIa-48L/R/H phenotype
  publication-title: Blood
  doi: 10.1182/blood.V90.3.1109
  contributor:
    fullname: Koene
– volume: 70
  year: 2019
  ident: B165
  article-title: Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma
  publication-title: Hepatology
  doi: 10.1002/hep.30347
  contributor:
    fullname: Sun
– volume: 10
  year: 2018
  ident: B174
  article-title: Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
  publication-title: Sci Trans Med
  doi: 10.1126/scitranslmed.aat5775
  contributor:
    fullname: Slaga
– volume: 22
  start-page: e4
  year: 2022
  ident: B222
  article-title: Development of bispecific antibody for cancer immunotherapy: focus on T cell engaging antibody
  publication-title: Immune Netw
  doi: 10.4110/in.2022.22.e4
  contributor:
    fullname: Moon
– volume: 2016
  start-page: 7470124
  year: 2016
  ident: B129
  article-title: NKG2C+CD57+ natural killer cell expansion parallels cytomegalovirus-specific CD8+ T cell evolution towards senescence
  publication-title: J Immunol Res
  doi: 10.1155/2016/7470124
  contributor:
    fullname: Heath
– volume: 7
  year: 2016
  ident: B145
  article-title: Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00413
  contributor:
    fullname: Rocca
– volume: 28
  year: 2014
  ident: B35
  article-title: Efficient generation of human natural killer cell lines by viral transformation
  publication-title: Leukemia
  doi: 10.1038/leu.2013.188
  contributor:
    fullname: Vogel
– volume: 7
  year: 2006
  ident: B121
  article-title: Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction
  publication-title: Nat Immunol
  doi: 10.1038/ni1402
  contributor:
    fullname: Welte
– volume: 85
  year: 1988
  ident: B185
  article-title: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain fv analogue produced in escherichia coli
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.85.16.5879
  contributor:
    fullname: Huston
– volume: 13
  start-page: 3994
  year: 2021
  ident: B56
  article-title: A HER2 tri-specific NK cell engager mediates efficient targeting of human ovarian cancer
  publication-title: Cancers
  doi: 10.3390/cancers13163994
  contributor:
    fullname: Vallera
– volume: 173
  year: 2004
  ident: B136
  article-title: Cutting edge: engagement of CD160 by its HLA-c physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell Subset1
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.9.5349
  contributor:
    fullname: Barakonyi
– volume: 8
  year: 2018
  ident: B2
  article-title: Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00086
  contributor:
    fullname: Seidel
– volume: 119
  year: 2012
  ident: B210
  article-title: Immunopharmacologic response of patients with b-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab
  publication-title: Blood
  doi: 10.1182/blood-2012-01-400515
  contributor:
    fullname: Klinger
– volume: 156
  year: 1996
  ident: B14
  article-title: A triallelic fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell fc gamma RIIIa
  publication-title: J Immunol
  doi: 10.4049/jimmunol.156.8.2948
  contributor:
    fullname: de Haas
– volume: 12
  year: 2021
  ident: B34
  article-title: CAR-NK cells: from natural basis to design for kill
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.707542
  contributor:
    fullname: Khawar
– volume: 4
  year: 2015
  ident: B152
  article-title: B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2014.1001224
  contributor:
    fullname: Pesce
– volume: 175
  start-page: 1731
  year: 2018
  ident: B156
  article-title: Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
  publication-title: Cell
  doi: 10.1016/j.cell.2018.10.014
  contributor:
    fullname: André
– volume: 367
  year: 2020
  ident: B181
  article-title: Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
  publication-title: Science
  doi: 10.1126/science.aaz9356
  contributor:
    fullname: Rougé
– volume: 33
  start-page: 74
  year: 2015
  ident: B147
  article-title: Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.57.3329
  contributor:
    fullname: Conlon
– volume: 67
  start-page: 95
  year: 2015
  ident: B218
  article-title: Alternative molecular formats and therapeutic applications for bispecific antibodies
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2015.01.003
  contributor:
    fullname: Spiess
– volume: 31
  year: 2013
  ident: B199
  article-title: Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2621
  contributor:
    fullname: Spiess
– volume: 6
  year: 2016
  ident: B167
  article-title: Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-15-0944
  contributor:
    fullname: Blake
– volume: 21
  year: 2003
  ident: B30
  article-title: Two immunoglobulin G fragment c receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2003.05.013
  contributor:
    fullname: Weng
– volume: 12
  year: 2020
  ident: B217
  article-title: Fc-engineered antibodies with enhanced fc-effector function for the treatment of b-cell malignancies
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12103041
  contributor:
    fullname: van der Horst
– volume: 31
  year: 2013
  ident: B130
  article-title: Controlling natural killer cell responses: integration of signals for activation and inhibition
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev-immunol-020711-075005
  contributor:
    fullname: Long
– volume: 10
  start-page: 12
  year: 2022
  ident: B32
  article-title: CAR-NK cells for cancer immunotherapy: from bench to bedside
  publication-title: biomark Res
  doi: 10.1186/s40364-022-00364-6
  contributor:
    fullname: Zhang
– volume: 9
  year: 2018
  ident: B74
  article-title: Tribody [(HER2)2xCD16] is more effective than trastuzumab in enhancing γδ T cell and natural killer cell cytotoxicity against HER2-expressing cancer cells
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.00814
  contributor:
    fullname: Oberg
– volume: 43
  year: 2020
  ident: B67
  article-title: BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma
  publication-title: J Immunother
  doi: 10.1097/CJI.0000000000000320
  contributor:
    fullname: Wang
– volume: 138
  start-page: 2773
  year: 2021
  ident: B43
  article-title: Human placental CD34 +-derived natural killer cells with high affinity and cleavage resistant CD16 (CYNK-101) in combination with daratumumab for immunotherapy against CD38 expressing hematological malignancies
  publication-title: Blood
  doi: 10.1182/blood-2021-148869
  contributor:
    fullname: Raitman
– volume: 9
  year: 2018
  ident: B37
  article-title: NKG2D: a master regulator of immune cell responsiveness
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.00441
  contributor:
    fullname: Wensveen
– volume: 71
  year: 2011
  ident: B116
  article-title: Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-4179
  contributor:
    fullname: Platonova
– volume: 15
  start-page: 164
  year: 2022
  ident: B24
  article-title: Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01382-5
  contributor:
    fullname: Lamers-Kok
– volume: 278
  year: 2003
  ident: B114
  article-title: Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M308491200
  contributor:
    fullname: Foster
– volume: 6
  year: 2020
  ident: B88
  article-title: Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
  publication-title: Sci Adv
  doi: 10.1126/sciadv.aba8564
  contributor:
    fullname: Au
– volume: 109
  year: 2006
  ident: B117
  article-title: Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
  publication-title: Blood
  doi: 10.1182/blood-2005-08-027979
  contributor:
    fullname: Fauriat
– volume: 52
  year: 2010
  ident: B162
  article-title: T Cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis b
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2009.12.005
  contributor:
    fullname: Ju
– volume: 177
  year: 2020
  ident: B111
  article-title: NKp30 - a prospective target for new cancer immunotherapy strategies
  publication-title: Br J Pharmacol
  doi: 10.1111/bph.15222
  contributor:
    fullname: Pinheiro
– volume: 212
  year: 2015
  ident: B134
  article-title: CD160 is essential for NK-mediated IFN-γ production
  publication-title: J Exp Med
  doi: 10.1084/jem.20131601
  contributor:
    fullname: Tu
– volume: 16
  start-page: 7
  year: 2016
  ident: B10
  article-title: NK cells and cancer: you can teach innate cells new tricks
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2015.5
  contributor:
    fullname: Morvan
– volume: 13
  year: 2022
  ident: B25
  article-title: Focusing on NK cells and ADCC: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.1083462
  contributor:
    fullname: Li
– volume: 132
  year: 2018
  ident: B94
  article-title: Preclinical characterization of AFM26, a novel b cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma
  publication-title: Blood
  doi: 10.1182/blood-2018-99-118970
  contributor:
    fullname: Ross
– volume: 82
  year: 2022
  ident: B215
  article-title: Abstract CT003: innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2022-CT003
  contributor:
    fullname: Nieto
– volume: 282
  year: 2007
  ident: B211
  article-title: Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M700820200
  contributor:
    fullname: Müller
– volume: 128
  year: 2007
  ident: B206
  article-title: Selection and characterization of affibody ligands binding to Alzheimer amyloid β peptides
  publication-title: J Biotechnol
  doi: 10.1016/j.jbiotec.2006.09.013
  contributor:
    fullname: Grönwall
– volume: 22
  year: 2011
  ident: B209
  article-title: Strategies for extended serum half-life of protein therapeutics
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2011.06.012
  contributor:
    fullname: Kontermann
– volume: 106
  year: 2005
  ident: B45
  article-title: Arf6: a new player in FcγRIIIA lymphocyte-mediated cytotoxicity
  publication-title: Blood
  doi: 10.1182/blood-2004-10-4100
  contributor:
    fullname: Galandrini
– volume: 6
  year: 2018
  ident: B54
  article-title: A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-17-0649
  contributor:
    fullname: Chan
– volume: 9
  year: 2018
  ident: B146
  article-title: IL-15 overcomes hepatocellular carcinoma-induced NK cell dysfunction
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.01009
  contributor:
    fullname: Easom
– volume: 34
  start-page: 985
  year: 2020
  ident: B176
  article-title: B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0734-z
  contributor:
    fullname: Shah
– volume: 146
  year: 1991
  ident: B44
  article-title: Analysis of fc gamma RIII (CD16) membrane expression and association with CD3 zeta and fc epsilon RI-gamma by site-directed mutation
  publication-title: J Immunol
  doi: 10.4049/jimmunol.146.5.1571
  contributor:
    fullname: Lanier
– volume: 6
  year: 2015
  ident: B127
  article-title: Polyclonal expansion of NKG2C+ NK cells in TAP-deficient patients
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2015.00507
  contributor:
    fullname: Béziat
– volume: 8
  year: 2019
  ident: B220
  article-title: Design and production of bispecific antibodies
  publication-title: Antibodies (Basel)
  doi: 10.3390/antib8030043
  contributor:
    fullname: Wang
– volume: 36
  start-page: 3
  year: 2005
  ident: B223
  article-title: Immunogenicity of engineered antibodies
  publication-title: Methods
  doi: 10.1016/j.ymeth.2005.01.001
  contributor:
    fullname: Hwang
– volume: 22
  year: 2022
  ident: B39
  article-title: Natural killer cells in antitumour adoptive cell immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-022-00491-0
  contributor:
    fullname: Laskowski
– volume: 7
  year: 2018
  ident: B180
  article-title: IgG antibody 3D structures and dynamics
  publication-title: Antibodies (Basel)
  doi: 10.3390/antib7020018
  contributor:
    fullname: Jay
– volume: 30
  year: 2017
  ident: B77
  article-title: Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
  publication-title: Protein Engineering Design Selection
  doi: 10.1093/protein/gzx043
  contributor:
    fullname: Gantke
– volume: 190
  year: 1999
  ident: B109
  article-title: Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells
  publication-title: J Exp Med
  doi: 10.1084/jem.190.10.1505
  contributor:
    fullname: Pende
– volume: 86
  year: 1990
  ident: B101
  article-title: Soluble fc gamma receptor III in human plasma originates from release by neutrophils
  publication-title: J Clin Invest
  doi: 10.1172/JCI114727
  contributor:
    fullname: Huizinga
– volume: 217
  year: 2018
  ident: B98
  article-title: Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
  publication-title: J Cell Biol
  doi: 10.1083/jcb.201712085
  contributor:
    fullname: Srpan
– volume: 66
  year: 2006
  ident: B208
  article-title: Tumor imaging using a picomolar affinity HER2 binding affibody molecule
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-3521
  contributor:
    fullname: Orlova
– volume: 128
  start-page: 1836
  year: 2016
  ident: B173
  article-title: CD20 tcb (RG6026), a novel "2:1" T cell bispecific antibody for the treatment of b cell malignancies
  publication-title: Blood
  doi: 10.1182/blood.V128.22.1836.1836
  contributor:
    fullname: Bacac
– volume: 359
  year: 2008
  ident: B27
  article-title: Targeting EGFR in colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMe0806778
  contributor:
    fullname: Messersmith
– volume: 100
  year: 1997
  ident: B12
  article-title: A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease
  publication-title: J Clin Invest
  doi: 10.1172/JCI119616
  contributor:
    fullname: Wu
– volume: 44
  year: 2007
  ident: B202
  article-title: The change of the scFv into the fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2006.05.009
  contributor:
    fullname: Quintero-Hernández
– volume: 107
  year: 2006
  ident: B90
  article-title: A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
  publication-title: Blood
  doi: 10.1182/blood-2005-05-2177
  contributor:
    fullname: von Strandmann
– volume: 29
  year: 2021
  ident: B62
  article-title: Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C(+) NK cells to target myeloid leukemia
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2021.06.018
  contributor:
    fullname: Chiu
– volume: 120
  year: 2012
  ident: B51
  article-title: Bi-specific killer cell engagers (BiKEs) signaling through CD16 and targeting CD33 (CD16 × CD33), triggers natural killer (NK) cell cytotoxic and cytokine production against refractory acute myeloid leukemia (AML)
  publication-title: Blood
  doi: 10.1182/blood.V120.21.256.256
  contributor:
    fullname: Wiernik
– volume: 79
  year: 2019
  ident: B84
  article-title: Abstract 4972: preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2019-4972
  contributor:
    fullname: Draghi
– volume: 10
  start-page: 693
  year: 2018
  ident: B31
  article-title: The "less-is-more" in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
  publication-title: MAbs
  doi: 10.1080/19420862.2018.1466767
  contributor:
    fullname: Pereira
– volume: 209
  year: 2022
  ident: B133
  article-title: KIR2DS2 expression identifies NK cells with enhanced anticancer activity
  publication-title: J Immunol
  doi: 10.4049/jimmunol.2101139
  contributor:
    fullname: Blunt
– volume: 12
  year: 2021
  ident: B81
  article-title: Design of a trispecific checkpoint inhibitor and natural killer cell engager based on a 2 + 1 common light chain antibody architecture
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.669496
  contributor:
    fullname: Bogen
– volume: 80
  start-page: 100870
  year: 2021
  ident: B132
  article-title: NK cells and ILCs in tumor immunotherapy
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2020.100870
  contributor:
    fullname: Sivori
– volume: 18
  start-page: 585
  year: 2019
  ident: B219
  article-title: Bispecific antibodies: a mechanistic review of the pipeline
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-019-0028-1
  contributor:
    fullname: Labrijn
– volume: 23
  year: 2018
  ident: B4
  article-title: Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2018.02.012
  contributor:
    fullname: Zheng
– volume: 10
  start-page: 291
  year: 2022
  ident: B80
  article-title: Exploiting natural killer cell engagers to control pediatric b-cell precursor acute lymphoblastic leukemia
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-21-0843
  contributor:
    fullname: Colomar-Carando
– volume: 2016
  year: 2016
  ident: B23
  article-title: Can we make a better match or mismatch with KIR genotyping
  publication-title: Hematol Am Soc Hematol Educ Program
  doi: 10.1182/asheducation-2016.1.106
  contributor:
    fullname: Mehta
– volume: 23
  year: 2005
  ident: B205
  article-title: Engineering novel binding proteins from nonimmunoglobulin domains
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1127
  contributor:
    fullname: Binz
– volume: 76
  year: 2016
  ident: B93
  article-title: Abstract 580: anti-EGFRvIII TandAbs recruiting either T or NK cells are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII+ tumors
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.AM2016-580
  contributor:
    fullname: Ellwanger
– volume: 276
  start-page: 97
  year: 2017
  ident: B159
  article-title: Tim-3 and its role in regulating anti-tumor immunity
  publication-title: Immunol Rev
  doi: 10.1111/imr.12520
  contributor:
    fullname: Das
– volume: 7
  year: 2007
  ident: B216
  article-title: FcRn: the neonatal fc receptor comes of age
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2155
  contributor:
    fullname: Roopenian
– volume: 26
  year: 2008
  ident: B29
  article-title: Immunoglobulin G fragment c receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.14.8957
  contributor:
    fullname: Musolino
– volume: 12
  start-page: 2659
  year: 2020
  ident: B57
  article-title: NK-Cell-Mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo
  publication-title: Cancers
  doi: 10.3390/cancers12092659
  contributor:
    fullname: Vallera
– volume: 7
  start-page: 28
  year: 2018
  ident: B198
  article-title: Engineering IgG-like bispecific antibodies–an overview
  publication-title: Antibodies
  doi: 10.3390/antib7030028
  contributor:
    fullname: Krah
– volume: 80
  year: 2008
  ident: B183
  article-title: Engineering peptide linkers for scFv immunosensors
  publication-title: Anal Chem
  doi: 10.1021/ac7018624
  contributor:
    fullname: Shen
– volume: 9
  year: 2020
  ident: B182
  article-title: A dynamic interaction between CD19 and the tetraspanin CD81 controls b cell co-receptor trafficking
  publication-title: eLife
  doi: 10.7554/eLife.52337.sa2
  contributor:
    fullname: Susa
– volume: 3
  start-page: 2
  year: 2018
  ident: B148
  article-title: Targeting IL-2: an unexpected effect in treating immunological diseases
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-017-0002-5
  contributor:
    fullname: Ye
– volume: 1441
  year: 2016
  ident: B189
  article-title: Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-3684-7_28
  contributor:
    fullname: Felices
– volume: 170
  year: 2003
  ident: B177
  article-title: The size of the synaptic cleft and distinct distributions of filamentous actin, ezrin, CD43, and CD45 at activating and inhibitory human NK cell immune synapses 12
  publication-title: J Immunol
  doi: 10.4049/jimmunol.170.6.2862
  contributor:
    fullname: McCann
– volume: 134
  year: 2019
  ident: B83
  article-title: CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2019-128749
  contributor:
    fullname: Watkins-Yoon
– volume: 118
  year: 2006
  ident: B108
  article-title: Soluble MICA in malignant diseases
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21382
  contributor:
    fullname: Holdenrieder
– volume: 13
  year: 2022
  ident: B36
  article-title: Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.1039969
  contributor:
    fullname: Nikkhoi
– volume: 17
  year: 2020
  ident: B64
  article-title: Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
  publication-title: Cancer Biol Med
  doi: 10.20892/j.issn.2095-3941.2020.0399
  contributor:
    fullname: Cheng
– volume: 290
  year: 2015
  ident: B122
  article-title: Generation and preclinical characterization of an NKp80-fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M115.678912
  contributor:
    fullname: Deng
– volume: 6
  year: 2014
  ident: B69
  article-title: A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
  publication-title: MAbs
  doi: 10.4161/mabs.28591
  contributor:
    fullname: Reusch
– volume: 8
  start-page: 357ra123
  year: 2016
  ident: B150
  article-title: Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
  publication-title: Sci Trans Med
  doi: 10.1126/scitranslmed.aaf2341
  contributor:
    fullname: Romee
– volume: 12
  start-page: 195
  year: 2018
  ident: B221
  article-title: Bispecific antibodies: design, therapy, perspectives
  publication-title: Drug Des Devel Ther
  doi: 10.2147/DDDT.S151282
  contributor:
    fullname: Sedykh
– volume: 9
  year: 1996
  ident: B194
  article-title: ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
  publication-title: Protein Engineering Design Selection
  doi: 10.1093/protein/9.7.617
  contributor:
    fullname: Ridgway
– volume: 47
  year: 2017
  ident: B19
  article-title: The broad spectrum of human natural killer cell diversity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2017.10.008
  contributor:
    fullname: Freud
– volume: 13
  start-page: 5446
  year: 2021
  ident: B55
  article-title: Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor
  publication-title: Cancers
  doi: 10.3390/cancers13215446
  contributor:
    fullname: Toffoli
– volume: 5
  start-page: 5479
  year: 2014
  ident: B178
  article-title: The immune synapse clears and excludes molecules above a size threshold
  publication-title: Nat Commun
  doi: 10.1038/ncomms6479
  contributor:
    fullname: Cartwright
– volume: 7
  year: 2016
  ident: B60
  article-title: Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12073
  contributor:
    fullname: Schmohl
– volume: 24
  year: 2018
  ident: B120
  article-title: Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo–expanded autologous NK cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-3117
  contributor:
    fullname: Wang
– volume: 36
  year: 2022
  ident: B73
  article-title: A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
  publication-title: Leukemia
  doi: 10.1038/s41375-021-01478-w
  contributor:
    fullname: Kakiuchi-Kiyota
– volume: 12
  start-page: 996
  year: 2023
  ident: B86
  article-title: Derivation and preclinical characterization of CYT-303, a novel NKp46-NK cell engager targeting GPC3
  publication-title: Cells
  doi: 10.3390/cells12070996
  contributor:
    fullname: Arulanandam
– volume: 20
  year: 2019
  ident: B163
  article-title: IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(19)30320-1
  contributor:
    fullname: Bagot
– volume: 16
  year: 2019
  ident: B155
  article-title: The NKG2A immune checkpoint [[/amp]]mdash; a new direction in cancer immunotherapy
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-019-0182-8
  contributor:
    fullname: Creelan
– volume: 17
  start-page: 19
  year: 2002
  ident: B106
  article-title: The role of the NKG2D immunoreceptor in immune cell activation and natural killing
  publication-title: Immunity
  doi: 10.1016/S1074-7613(02)00333-3
  contributor:
    fullname: Jamieson
– volume: 203
  start-page: 46
  year: 1991
  ident: B184
  article-title: Protein engineering of single-chain fv analogs and fusion proteins
  publication-title: Methods Enzymol
  doi: 10.1016/0076-6879(91)03005-2
  contributor:
    fullname: Huston
– volume: 19
  start-page: 19
  year: 2020
  ident: B3
  article-title: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-1144-6
  contributor:
    fullname: Ren
– volume: 90
  start-page: 11.9B.1
  year: 2010
  ident: B102
  article-title: Signal transduction during activation and inhibition of natural killer cells
  publication-title: Curr Protoc Immunol
  doi: 10.1002/0471142735.im1109bs90
  contributor:
    fullname: Watzl
– volume: 206
  year: 2021
  ident: B82
  article-title: Affinity maturation of B7-H6 translates into enhanced NK cell-mediated tumor cell lysis and improved proinflammatory cytokine release of bispecific immunoligands via NKp30 engagement
  publication-title: J Immunol
  doi: 10.4049/jimmunol.2001004
  contributor:
    fullname: Pekar
– volume: 188
  year: 1998
  ident: B46
  article-title: The vav-Rac1 pathway in cytotoxic lymphocytes regulates the generation of cell-mediated killing
  publication-title: J Exp Med
  doi: 10.1084/jem.188.3.549
  contributor:
    fullname: Billadeau
– volume: 140
  year: 2022
  ident: B58
  article-title: Affibody-based BCMA x CD16 dual engagers for activation of NK cells towards multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2022-164753
  contributor:
    fullname: Giang
– volume: 191
  year: 2013
  ident: B97
  article-title: Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1300313
  contributor:
    fullname: Peruzzi
– volume: 76
  year: 2016
  ident: B158
  article-title: Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-0839
  contributor:
    fullname: Sarhan
– volume: 96
  year: 2015
  ident: B170
  article-title: Super-resolution imaging of the natural killer cell immunological synapse on a glass-supported planar lipid bilayer
  publication-title: J Vis Exp
  doi: 10.3791/52502-v
  contributor:
    fullname: Zheng
– volume: 13
  start-page: 1950264
  year: 2021
  ident: B70
  article-title: Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
  publication-title: MAbs
  doi: 10.1080/19420862.2021.1950264
  contributor:
    fullname: Wingert
– volume: 13
  year: 2021
  ident: B87
  article-title: Bispecific antibody designed for targeted NK cell activation and functional assessment for biomedical applications
  publication-title: ACS Appl Materials Interfaces
  doi: 10.1021/acsami.1c08986
  contributor:
    fullname: Song
– volume: 49
  year: 2017
  ident: B59
  article-title: Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity
  publication-title: Cancer Res Treat
  doi: 10.4143/crt.2016.491
  contributor:
    fullname: Schmohl
– volume: 10
  year: 2021
  ident: B227
  article-title: Affecting HEK293 cell growth and production performance by modifying the expression of specific genes
  publication-title: Cells
  doi: 10.3390/cells10071667
  contributor:
    fullname: Abaandou
– volume: 186
  year: 2011
  ident: B123
  article-title: Cutting edge: NKp80 uses an atypical hemi-ITAM to trigger NK cytotoxicity
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0904117
  contributor:
    fullname: Dennehy
– volume: 7
  year: 2008
  ident: B212
  article-title: Improved tumor targeting of anti–epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-07-2384
  contributor:
    fullname: Tijink
– volume: 9
  year: 2021
  ident: B226
  article-title: HEK293 cell line as a platform to produce recombinant proteins and viral vectors
  publication-title: Front Bioengineering Biotechnol
  doi: 10.3389/fbioe.2021.796991
  contributor:
    fullname: Tan
– volume: 10
  year: 2019
  ident: B110
  article-title: The natural cytotoxicity receptors in health and disease
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2019.00909
  contributor:
    fullname: Barrow
– volume: 196
  year: 2016
  ident: B128
  article-title: Relationship of NKG2C copy number with the distribution of distinct cytomegalovirus-induced adaptive NK cell subsets
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1502438
  contributor:
    fullname: Muntasell
– volume: 19
  year: 2013
  ident: B99
  article-title: Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-0505
  contributor:
    fullname: Wiernik
– volume: 125
  year: 2015
  ident: B91
  article-title: A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2014-12-614636
  contributor:
    fullname: Rothe
– volume: 151
  year: 1993
  ident: B11
  article-title: Binding of monomeric human IgG defines an expression polymorphism of fc gamma RIII on large granular lymphocyte/natural killer cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.151.11.6429
  contributor:
    fullname: Vance
– volume: 271
  year: 1996
  ident: B190
  article-title: Selection of linkers for a catalytic single-chain antibody using phage display technology
  publication-title: J Biol Chem
  doi: 10.1074/jbc.271.26.15682
  contributor:
    fullname: Tang
– volume: 27
  year: 2021
  ident: B40
  article-title: Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) malignancies
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-21-0164
  contributor:
    fullname: Kerbauy
– volume: 12
  start-page: 5449
  year: 2022
  ident: B188
  article-title: Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv
  publication-title: Sci Rep
  doi: 10.1038/s41598-022-09324-4
  contributor:
    fullname: Arslan
– volume: 18
  year: 2019
  ident: B153
  article-title: PD-L1 expression levels on tumor cells affect their immunosuppressive activity
  publication-title: Oncol Lett
  doi: 10.3892/ol.2019.10903
  contributor:
    fullname: Zheng
– volume: 23
  start-page: 195
  year: 2010
  ident: B195
  article-title: SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
  publication-title: Protein Engineering Design Selection
  doi: 10.1093/protein/gzp094
  contributor:
    fullname: Davis
– volume: 99
  year: 2002
  ident: B135
  article-title: Engagement of CD160 receptor by HLA-c is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.012681099
  contributor:
    fullname: Le Bouteiller
– volume: 3
  start-page: 897
  year: 2019
  ident: B63
  article-title: Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2018029371
  contributor:
    fullname: Felices
– volume: 8
  year: 2008
  ident: B169
  article-title: Formation and function of the lytic NK-cell immunological synapse
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2381
  contributor:
    fullname: Orange
– volume: 285
  year: 2010
  ident: B196
  article-title: Enhancing antibody fc heterodimer formation through electrostatic steering effects: application to bispecific molecules and monovalent IgG
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M110.117382
  contributor:
    fullname: Gunasekaran
– volume: 3
  year: 2012
  ident: B142
  article-title: Evolving role of 2B4/CD244 in T and NK cell responses during virus infection
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2012.00377
  contributor:
    fullname: Waggoner
– volume: 12
  year: 2022
  ident: B161
  article-title: Tim-3 blockade elicits potent anti-multiple myeloma immunity of natural killer cells
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.739976
  contributor:
    fullname: Jiang
– volume: 3
  year: 2012
  ident: B149
  article-title: Molecular mechanisms of treg-mediated T cell suppression
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2012.00051
  contributor:
    fullname: Schmidt
– volume: 7
  start-page: 105
  year: 2019
  ident: B26
  article-title: NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives
  publication-title: Ann Transl Med
  doi: 10.21037/atm.2019.01.42
  contributor:
    fullname: Lo Nigro
– volume: 168
  year: 2002
  ident: B105
  article-title: UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.168.2.671
  contributor:
    fullname: Sutherland
– volume: 19
  year: 2018
  ident: B157
  article-title: Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
  publication-title: Nat Immunol
  doi: 10.1038/s41590-018-0132-0
  contributor:
    fullname: Zhang
– volume: 21
  year: 2015
  ident: B175
  article-title: Immune escape mechanisms as a guide for cancer immunotherapy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-14-1860
  contributor:
    fullname: Beatty
– volume-title: Methods in enzymology
  year: 1986
  ident: B192
  article-title: Bispecific monoclonal antibodies from hybrid hybridomas
  contributor:
    fullname: Suresh
– volume: 11
  year: 2012
  ident: B52
  article-title: Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-12-0692
  contributor:
    fullname: Gleason
– volume: 11
  start-page: 132
  year: 2018
  ident: B9
  article-title: Universal CARs, universal T cells, and universal CAR T cells
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-018-0677-2
  contributor:
    fullname: Zhao
– volume: 128
  year: 2016
  ident: B76
  article-title: Trispecific antibodies for selective CD16A-directed NK-cell engagement in multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood.V128.22.4513.4513
  contributor:
    fullname: Gantke
– volume: 7
  year: 2018
  ident: B164
  article-title: CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1424677
  contributor:
    fullname: Roman Aguilera
– volume: 9
  year: 2020
  ident: B115
  article-title: Understanding the synergy of NKp46 and Co-activating signals in various NK cell subpopulations: paving the way for more successful NK-Cell-Based immunotherapy
  publication-title: Cells
  doi: 10.3390/cells9030753
  contributor:
    fullname: Zamai
– volume: 21
  start-page: 194
  year: 2022
  ident: B1
  article-title: The journey of CAR-T therapy in hematological malignancies
  publication-title: Mol Cancer
  doi: 10.1186/s12943-022-01663-0
  contributor:
    fullname: Lu
– volume: 76
  year: 2004
  ident: B113
  article-title: Rat NKp46 activates natural killer cell cytotoxicity and is associated with FcεRIγ and CD3ζ
  publication-title: J Leukocyte Biol
  doi: 10.1189/jlb.0903428
  contributor:
    fullname: Westgaard
– volume: 251
  year: 2013
  ident: B107
  article-title: Dynamics of NK cell interactions in vivo
  publication-title: Immunol Rev
  doi: 10.1111/imr.12015
  contributor:
    fullname: Deguine
– volume: 6
  year: 1993
  ident: B186
  article-title: An improved linker for single-chain fv with reduced aggregation and enhanced proteolytic stability
  publication-title: Protein Engineering Design Selection
  doi: 10.1093/protein/6.8.989
  contributor:
    fullname: Whitlow
– volume: 22
  year: 2019
  ident: B7
  article-title: CAR T-cells: costs, comparisons, and commentary
  publication-title: J Med Econ
  doi: 10.1080/13696998.2019.1582059
  contributor:
    fullname: Hay
– volume: 22
  year: 2016
  ident: B38
  article-title: IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-2710
  contributor:
    fullname: Vallera
– volume: 99
  year: 2002
  ident: B28
  article-title: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG fc receptor FcγRIIIa gene
  publication-title: Blood
  doi: 10.1182/blood.V99.3.754
  contributor:
    fullname: Cartron
– volume: 21
  year: 2007
  ident: B95
  article-title: CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404499
  contributor:
    fullname: Grzywacz
– volume: 105
  year: 2005
  ident: B141
  article-title: Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and nectin-2 (CD112)
  publication-title: Blood
  doi: 10.1182/blood-2004-09-3548
  contributor:
    fullname: Pende
– volume: 1844
  year: 2014
  ident: B191
  article-title: Engineering disulfide bonds within an antibody
  publication-title: Biochim Biophys Acta (BBA) - Proteins Proteomics
  doi: 10.1016/j.bbapap.2014.07.005
  contributor:
    fullname: Hagihara
– volume: 4
  year: 1996
  ident: B139
  article-title: DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)70060-4
  contributor:
    fullname: Shibuya
– volume: 24
  year: 2004
  ident: B144
  article-title: Molecular dissection of 2B4 signaling: implications for signal transduction by SLAM-related receptors
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.24.12.5144-5156.2004
  contributor:
    fullname: Chen
– volume: 22
  year: 2008
  ident: B214
  article-title: The impact of PEGylation on biological therapies
  publication-title: BioDrugs
  doi: 10.2165/00063030-200822050-00004
  contributor:
    fullname: Veronese
– volume: 35
  year: 2021
  ident: B61
  article-title: A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
  publication-title: Leukemia
  doi: 10.1038/s41375-020-01065-5
  contributor:
    fullname: Arvindam
– volume: 63
  year: 2022
  ident: B92
  article-title: AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
  publication-title: Leukemia Lymphoma
  doi: 10.1080/10428194.2022.2095623
  contributor:
    fullname: Sasse
– volume: 15
  year: 2019
  ident: B6
  article-title: Current progress in CAR-T cell therapy for solid tumors
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.34213
  contributor:
    fullname: Ma
– volume: 47
  start-page: 1
  year: 2020
  ident: B131
  article-title: Activating killer cell immunoglobulin-like receptors: detection, function and therapeutic use
  publication-title: Int J Immunogenetics
  doi: 10.1111/iji.12461
  contributor:
    fullname: Blunt
– volume: 11
  year: 2022
  ident: B42
  article-title: Cryopreservation of natural killer cells pre-complexed with innate cell engagers
  publication-title: Antibodies (Basel)
  doi: 10.3390/antib11010012
  contributor:
    fullname: Reusch
– volume: 49
  year: 2017
  ident: B204
  article-title: Affibody molecules as engineered protein drugs
  publication-title: Exp Mol Med
  doi: 10.1038/emm.2017.35
  contributor:
    fullname: Frejd
– volume: 7
  year: 2016
  ident: B126
  article-title: Features of memory-like and PD-1(+) human NK cell subsets
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00351
  contributor:
    fullname: Della Chiesa
– volume: 121
  year: 2013
  ident: B96
  article-title: NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
  publication-title: Blood
  doi: 10.1182/blood-2012-04-425397
  contributor:
    fullname: Romee
– volume: 212
  year: 2015
  ident: B140
  article-title: DNAM-1 controls NK cell activation via an ITT-like motif
  publication-title: J Exp Med
  doi: 10.1084/jem.20150792
  contributor:
    fullname: Zhang
– volume: 10
  year: 2010
  ident: B200
  article-title: Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2868
  contributor:
    fullname: Bachmann
– volume: 138
  year: 2011
  ident: B137
  article-title: CD160: a unique activating NK cell receptor
  publication-title: Immunol Lett
  doi: 10.1016/j.imlet.2011.02.003
  contributor:
    fullname: Le Bouteiller
– volume: 177
  start-page: 1701
  year: 2019
  ident: B79
  article-title: Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity
  publication-title: Cell
  doi: 10.1016/j.cell.2019.04.041
  contributor:
    fullname: Gauthier
– volume: 107
  year: 2006
  ident: B47
  article-title: Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
  publication-title: Blood
  doi: 10.1182/blood-2005-04-1351
  contributor:
    fullname: Bryceson
– volume: 106
  year: 2016
  ident: B112
  article-title: B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells
  publication-title: Pept Sci
  doi: 10.1002/bip.22879
  contributor:
    fullname: Phillips
– volume: 6
  year: 2015
  ident: B66
  article-title: HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5135
  contributor:
    fullname: Peipp
– volume: 7
  start-page: 12878
  year: 2016
  ident: B89
  article-title: Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
  publication-title: Nat Commun
  doi: 10.1038/ncomms12878
  contributor:
    fullname: Ghasemi
– volume: 58
  year: 2018
  ident: B8
  article-title: Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma
  publication-title: Transfusion
  doi: 10.1111/trf.14569
  contributor:
    fullname: Ceppi
– volume: 8
  start-page: 693
  year: 1998
  ident: B125
  article-title: Association of DAP12 with activating CD94/NKG2C NK cell receptors
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)80574-9
  contributor:
    fullname: Lanier
– volume: 13
  year: 2000
  ident: B100
  article-title: Crystal structure of the extracellular domain of a human FcyRIII
  publication-title: Immunity
  doi: 10.1016/S1074-7613(00)00038-8
  contributor:
    fullname: Zhang
– volume: 10
  start-page: 1854529
  year: 2020
  ident: B78
  article-title: Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2020.1854529
  contributor:
    fullname: Raynaud
– volume: 121
  year: 2011
  ident: B118
  article-title: Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
  publication-title: J Clin Invest
  doi: 10.1172/JCI45816
  contributor:
    fullname: Mamessier
– volume: 140
  year: 2022
  ident: B119
  article-title: Biological characterization and differential gene expression analysis of CYT-338 NK cell engager (NKE) against CD38 expressing tumors including multiple myeloma (MM)
  publication-title: Blood
  doi: 10.1182/blood-2022-170193
  contributor:
    fullname: Lin
– volume: 23
  start-page: 93
  year: 2009
  ident: B213
  article-title: Strategies to extend plasma half-lives of recombinant antibodies
  publication-title: BioDrugs
  doi: 10.2165/00063030-200923020-00003
  contributor:
    fullname: Kontermann
– volume: 43
  year: 2022
  ident: B15
  article-title: Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers
  publication-title: Trends Immunol
  doi: 10.1016/j.it.2022.09.007
  contributor:
    fullname: Pinto
– volume: 9
  start-page: 87
  year: 2021
  ident: B203
  article-title: A comprehensive comparison between camelid nanobodies and single chain variable fragments
  publication-title: biomark Res
  doi: 10.1186/s40364-021-00332-6
  contributor:
    fullname: Asaadi
– volume: 12
  year: 2012
  ident: B201
  article-title: The effect of antigen size on the immunogenicity of antigen presenting cell targeted DNA vaccine
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2011.08.016
  contributor:
    fullname: Jia
– volume: 11
  year: 2016
  ident: B53
  article-title: Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells
  publication-title: Target Oncol
  doi: 10.1007/s11523-015-0391-8
  contributor:
    fullname: Schmohl
– volume: 90
  year: 1993
  ident: B187
  article-title: "Diabodies": small bivalent and bispecific antibody fragments
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.90.14.6444
  contributor:
    fullname: Holliger
– volume: 17
  year: 2020
  ident: B193
  article-title: Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-020-0417-8
  contributor:
    fullname: Li
– volume: 21
  start-page: 8914
  year: 2020
  ident: B75
  article-title: Functional domain order of an anti-EGFR × anti-CD16 bispecific diabody involving NK cell activation
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21238914
  contributor:
    fullname: Kuwahara
– volume: 2
  year: 2018
  ident: B65
  article-title: Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2018018176
  contributor:
    fullname: Don Yun
– volume: 178
  year: 1993
  ident: B138
  article-title: A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity
  publication-title: J Exp Med
  doi: 10.1084/jem.178.3.1121
  contributor:
    fullname: Maïza
– volume: 19
  start-page: 120
  year: 2020
  ident: B17
  article-title: Natural killer cells in cancer biology and therapy
  publication-title: Mol Cancer
  doi: 10.1158/1557-3125.HIPPO19-IA12
  contributor:
    fullname: Wu
– volume: 24
  start-page: 100
  year: 2022
  ident: B72
  article-title: Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA/CD16A bispecific tetravalent antibody for the treatment of multiple myeloma
  publication-title: AAPS J
  doi: 10.1208/s12248-022-00744-8
  contributor:
    fullname: Cai
– volume: 108
  year: 2019
  ident: B224
  article-title: Immunogenicity of protein pharmaceuticals
  publication-title: J Pharm Sci
  doi: 10.1016/j.xphs.2018.12.014
  contributor:
    fullname: Dingman
– volume: 11
  year: 2021
  ident: B33
  article-title: From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.720501
  contributor:
    fullname: Lu
– volume: 10
  start-page: 10768
  year: 2020
  ident: B166
  article-title: CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-66806-z
  contributor:
    fullname: Liu
– volume: 53
  start-page: 548
  year: 2020
  ident: B172
  article-title: Multifaceted effects of antigen valency on b cell response composition and differentiation in vivo
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.08.001
  contributor:
    fullname: Kato
– volume: 171
  year: 2003
  ident: B151
  article-title: Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma 1
  publication-title: J Immunol
  doi: 10.4049/jimmunol.171.12.6891
  contributor:
    fullname: Doubrovina
– volume: 24
  year: 2010
  ident: B207
  article-title: Combining phage and staphylococcal surface display for generation of ErbB3-specific affibody molecules
  publication-title: Protein Engineering Design Selection
  doi: 10.1093/protein/gzq118
  contributor:
    fullname: Kronqvist
– volume: 105
  year: 2019
  ident: B20
  article-title: Mechanisms of natural killer cell-mediated cellular cytotoxicity
  publication-title: J Leukocyte Biol
  doi: 10.1002/JLB.MR0718-269R
  contributor:
    fullname: Prager
– volume: 14
  year: 2013
  ident: B179
  article-title: Matching cellular dimensions with molecular sizes
  publication-title: Nat Immunol
  doi: 10.1038/ni.2621
  contributor:
    fullname: Reth
– volume: 18
  year: 2018
  ident: B18
  article-title: Natural killer cells and other innate lymphoid cells in cancer
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-018-0061-z
  contributor:
    fullname: Chiossone
– volume: 8
  start-page: 96
  year: 2015
  ident: B68
  article-title: AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-015-0188-3
  contributor:
    fullname: Wu
– volume: 14
  year: 2022
  ident: B16
  article-title: Current progress of CAR-NK therapy in cancer treatment
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14174318
  contributor:
    fullname: Pang
– volume: 216
  year: 2019
  ident: B21
  article-title: NK cells switch from granzyme b to death receptor-mediated cytotoxicity during serial killing
  publication-title: J Exp Med
  doi: 10.1084/jem.20181454
  contributor:
    fullname: Prager
– volume: 123
  year: 2014
  ident: B50
  article-title: CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
  publication-title: Blood
  doi: 10.1182/blood-2013-10-533398
  contributor:
    fullname: Gleason
– volume: 3
  start-page: 16015
  year: 2016
  ident: B5
  article-title: Clinical manufacturing of CAR T cells: foundation of a promising therapy
  publication-title: Mol Ther Oncolytics
  doi: 10.1038/mto.2016.15
  contributor:
    fullname: Wang
– volume: 32
  year: 2013
  ident: B225
  article-title: Strategies for the production of recombinant protein in escherichia coli
  publication-title: Protein J
  doi: 10.1007/s10930-013-9502-5
  contributor:
    fullname: Gopal
– volume: 192
  year: 2000
  ident: B143
  article-title: X-Linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells
  publication-title: J Exp Med
  doi: 10.1084/jem.192.3.337
  contributor:
    fullname: Parolini
– volume: 4
  year: 2003
  ident: B103
  article-title: NKG2D-DAP10 triggers human NK cell–mediated killing via a syk-independent regulatory pathway
  publication-title: Nat Immunol
  doi: 10.1038/ni929
  contributor:
    fullname: Billadeau
– volume: 16
  year: 2019
  ident: B124
  article-title: Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-019-0206-4
  contributor:
    fullname: Sivori
– volume: 17
  start-page: 165
  year: 2019
  ident: B160
  article-title: TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
  publication-title: J Trans Med
  doi: 10.1186/s12967-019-1917-0
  contributor:
    fullname: Zheng
SSID ssj0000493335
Score 2.471042
SecondaryResourceType review_article
Snippet Natural Killer (NK) cells are a type of innate lymphoid cells that play a crucial role in immunity by killing virally infected or tumor cells and secreting...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 1207276
SubjectTerms cancer
functionality
Immunology
immunotherapy
manufacturability
natural killer (NK) cell
NK cell engager (NKCE)
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4iCF7EJ64vInhQpGubNG3jTZddFh97UthbSPPQFa3i7h789840VbYnL95KW9rmm9DvGzLzhZCTtNQGVDGLSuNYlFptojJJdMR56YENuc0FdiPfj7LhY3ozFuOFrb6wJizYAwfgLpiRnqW5TSzzaa6lLHPPgfWsMDIrbfj7xmwhmXoJupdzLkKXDGRh8sJP3t7mXdwsvJuwGFg7azFRbdjfUpntGskF0hmsk7VGLdKr8JUbZMlVm2Ql7B_5tUXuRrq2zaC3dUcf7bnXV9qvntCXYkpPR7e9_vTskmoK2pl6tCoAEqSTihqMNRxhc0jTgvW1TR4H_YfeMGq2R4gM5HAz4Bad4bJeAliURZFZWYjYcaxbE4XhDGCyWEGYO50VxtjYisynGvgHNBf6gu2Q5eq9cruEplqzWPpCGgbIOXicsKATCiu9YZy7Djn_gUp9BBcMBdkDAqtqYBUCqxpgO-Qa0fy9Ex2s6xMQV9XEVf0V1w45_omFghmPyxi6cu_zqWIwZkhDYSJ1SNEKUuuN7SvV5Ln2zobsU6AHz95_fOM-WcVx1_WA8oAszz7n7hA0yqw8qqfjN-4Y5Ag
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9tAEB3SlEIvoWlT4qQtW-ihIcixdrWStlBKahxC0_gUQ27Laj8cB0dO_AHxv--MJIcI2ktvwrJs7dtd3ht25g3Al6QwFlUxjwrreZQ4Y6Mijk0kRBGQDYXLJFUjXw7T81Hy61peb8Gm3VED4OKvoR31kxrNp93Hh_UP3PDfKeJEvj0Jk7u7VZf6gHdj3kNCTl_AS47MSClel43cv63VsBBC1rUz_3i0xU-VjX9Le7YzJ59R0dkb2Gk0JDutJ30Xtnz5Fl7VXSXX7-D30FRmGuyiqvNjfT-dskE5JreKBfs6vOgPFkffmGGoqFkgAwOkRjYpmaUVgFdUMtIUZq33YHQ2uOqfR03ThMhiZLdExjEpHfbFsZNFnqdO5bLnBWWzydwKHkTiKK8w8ybNrXU9J9OQGGQlVGLkFvYetstZ6feBJcbwngq5shyR8_hz0qF6yJ0KlgvhO3C8gUrf194YGmMKAlZXwGoCVjfAduAnofn0TfK1rj6Yzce62SaaWxV4krnY8ZBkRqkiwxcWOBar0sLxDnzezIXGfUCHG6b0s9VCcxwzBqe4vDqQtyap9Y_tO-XkpnLUxphUkjPPwf8_egivabRVbqD6ANvL-cp_RL2yLD5Vi_APDOHrPA
  priority: 102
  providerName: Scholars Portal
Title Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
URI https://search.proquest.com/docview/2858407373
https://pubmed.ncbi.nlm.nih.gov/PMC10450036
https://doaj.org/article/2c9f247d1d2f47a99b7f3431d5c96bd2
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Na9swFBdtobDL6NdYtrZosEPHcBLrw5Z6W0O60i6hhxVyE_rsMhKnNMmh_32fZHvU112EsS1b7wPe76H3fkLoKzPaAiommbGeZMxpm5k81xmlJkA0pK7ksRt5Mi1uHtjtjM92UNH2wqSifWvm_Wqx7FfzP6m28mlpB22d2OB-MoIUgkcilcEu2oX4-yZH_1tjXkoprztkIAOTgzBfLrf9eFB4PydDmFF0olAi6-8gzG595JuAc32A3jdIEf-oV3SIdnx1hPbrsyNfjtGvqU6UGfgudfPhkV8s8Lh6jJwUa3wxvRuN198uscaAm3GINAUQAPG8wjbaGa5iY0jTfvVygh6ux79HN1lzNEJmIX_bQFzRRdzSy3PHjRCFk4IPPY01a1xYSgJlLlYPll4Xwlo3dLwITEPsAbwVOcE-oL1qVfmPCDOtyVAGIS0BzXn4HHeAEYSTwRJKfQ99b1WlnmoGDAWZQ1SsSopVUbGqUWwPXUVt_nszslenG6vnR9XYUBErA2Glyx0JrNRSmhIWTEEWKwvjSA99aW2hwNvjFoau_Gq7VgRkhhQUnKiHRMdInT92n4AbJd7s1m0-_f_Uz-hdlDZVAMpTtLd53vozQCUbc56yeRh_znIYJ0ycJ7d8BUkY5a4
link.rule.ids 230,314,727,780,784,864,885,2102,24318,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VIkQvqLzUFCiLxAGEnMS7XtvLrY1SBfIQh1bqbbXPEpQ4VZMc-u-ZXduovnKz7LW9OzPS94125luAz5lWBlkxTbRxNMmsMolOU5Uwpj2iIbMFD93I80U-uc5-3vCbA8jbXphYtG_0sl-t1v1q-TvWVt6tzaCtExv8mo8wheBBSGXwBJ5yVoj0UZb-p2a9jDFe98hgDiYGfrle7_vhqPB-SoeI2XkHh6Jcf4djdiskH0HO5TG8aLgiOa_n9BIOXPUKntWnRz68htlCRdEMMo39fGTkVisyrm6DKsWWfFlMR-Pt1-9EEWTOxAehAoRAsqyICZ7Gq9Aa0jRgPbyB68vx1WiSNIcjJAYzuB0ii8rDpl6aWq7LMrei5EPHQtUaLw2jnmU21A8WTuWlMXZoee4zheiDjCuogr2Fw2pTuRMgmVJ0KHwpDEXLOfwct8gSSiu8oYy5HnxrTSXvag0MiblDMKyMhpXBsLIxbA8ugjX_jQz61fHG5v5WNl6U1AhPs8KmlvqsUELoAifMcC1G5NrSHnxqfSEx3sMmhqrcZr-VFNeMSSiGUQ_KjpM6f-w-wUCKytlt4Jz-_6sf4fnkaj6Tsx-L6Ts4CiuP9YDiPRzu7vfuA3KUnT6LAfkXVtLmQw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgEYgL4qktTyNxAKE0jR0nMTcorRa6W-2BlfZm-bkUtW61bQ_775lxUrS5cosSJ7FnRppv5G8-E_KhNNoCKmaZsZ5lpdM2M0WhM85NgGzIXS2wG_lsXp1clD8vxWXHqtx2tMpozWIYl6thXPxO3MrNyuYHnlh-fjaGEkKgkEq-cSG_S-4JDlF2q1L_0yJfzrlo-2SgDpN5WKxW-yEeFz4s2AjydtXLRUmyv4cz-yzJW2ln-pg86vAi_drO6wm54-NTcr89QfLmGTmd6yScQWepp4-O_XJJJ_EKlSm29ON8Np5sP32hmgJ6pgHFCiAN0kWkFr0NV9ge0jVh3TwnF9PJr_FJ1h2QkFmo4naQXXSFG3tF4YRpmsrJRow8R-aaaCxngZcOOYS111VjrRs5UYVSQwYC1IXKYC_IUVxHf0xoqTUbydBIy8ByHj4nHCCFxslgGed-QD4fTKU2rQ6GgvoBDauSYRUaVnWGHZBvaM1_I1HDOt1YX1-pzpOKWRlYWbvCsVDWWkpTw4Q5rMXKyjg2IO8PvlAQ87iRoaNf77eKwZqhEIVQGpCm56TeH_tPIJiSevYheF7-_6vvyIPz71N1-mM-e0Ue4sITJVC-Jke7671_AzBlZ96mePwLrcvnVg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+Killer+Cell+Engagers+%28NKCEs%29%3A+a+new+frontier+in+cancer+immunotherapy&rft.jtitle=Frontiers+in+immunology&rft.au=Zhang%2C+Minchuan&rft.au=Lam%2C+Kong-Peng&rft.au=Xu%2C+Shengli&rft.date=2023-08-09&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-3224&rft.volume=14&rft_id=info:doi/10.3389%2Ffimmu.2023.1207276&rft.externalDBID=PMC10450036
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon